<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37511443</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11682</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241411682</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an invariably fatal neurodegenerative disease with limited therapeutic options. There is an urgent need for novel biomarkers to be used as surrogates for new therapeutic trials and disease monitoring. In this study, we sought to systematically study creatine kinase isoenzyme MB (CK-MB) in a real-world cohort of ALS patients, assess the diagnostic performance, and evaluate its association with other laboratory and clinical parameters. We reviewed data from 194 consecutive patients that included 130 ALS patients and 64 disease control patients (primary lateral sclerosis [PLS], benign fasciculations syndrome [BFS], Huntington's disease [HD] and Alzheimer's disease [AD]). CK-MB was elevated in the sera of more than half of all patients with ALS. In patients with spinal-onset ALS, CK-MB levels were significantly higher than in patients with other neurodegenerative diseases. Patients with slower rates of functional decline had a significantly higher baseline CK-MB. Furthermore, CK-MB elevations correlated with cardiac troponin T (cTnT) and with revised ALS Functional Rating Scale (ALSFRS-R) bulbar subcategory. We posit that measuring CK-MB in ALS patients in a complimentary fashion could potentially aid in the diagnostic workup of ALS and help discriminate the disease from some ALS mimics and other neurodegenerative diseases. CK-MB levels also may provide valuable prognostic information regarding disease aggressiveness as well as correlations with specific phenotypic presentations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kittipeerapat</LastName><ForeName>Natsinee</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabian</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2344-5662</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-Gomez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1581-474X</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology II, University Hospital Bonn, 53115 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>390873048</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>21060</GrantID><Agency>Alzheimer Forschung Initiative</Agency><Country/></Grant><Grant><GrantID>0001</GrantID><Agency>Alle-Lieben-Schmidt e.V</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D052279">Creatine Kinase, MB Form</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052279" MajorTopicYN="N">Creatine Kinase, MB Form</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CK-MB isoenzyme</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">creatinine kinase (CK)</Keyword><Keyword MajorTopicYN="N">prognostic value</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37511443</ArticleId><ArticleId IdType="pmc">PMC10380590</ArticleId><ArticleId IdType="doi">10.3390/ijms241411682</ArticleId><ArticleId IdType="pii">ijms241411682</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Recent Advances in the Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. Lancet Neurol. 2022;21:480&#x2013;493. doi: 10.1016/S1474-4422(21)00465-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Genge A., Chio A. The Future of ALS Diagnosis and Staging: Where Do We Go from Here? Amyotroph. Lateral Scler. Front. Degener. 2023;24:165&#x2013;174. doi: 10.1080/21678421.2022.2150555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2150555</ArticleId><ArticleId IdType="pubmed">36503299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M., Kaddurah-Daouk R. Creatine and Creatinine Metabolism. Physiol. Rev. 2000;80:1107&#x2013;1213. doi: 10.1152/physrev.2000.80.3.1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2000.80.3.1107</ArticleId><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Dharmadasa T., Malaspina A., Shaw P.J., Talbot K., Turner M.R., Thompson A.G. Creatine Kinase and Prognosis in Amyotrophic Lateral Sclerosis: A Literature Review and Multi-Centre Cohort Analysis. J. Neurol. 2022;269:5395&#x2013;5404. doi: 10.1007/s00415-022-11195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11195-8</ArticleId><ArticleId IdType="pmc">PMC9467954</ArticleId><ArticleId IdType="pubmed">35614165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson D.M., Eppenberger H.M., Kaplan N.O. Creatine Kinase: Evidence for a Dimeric Structure. Biochem. Biophys. Res. Commun. 1965;21:346&#x2013;353. doi: 10.1016/0006-291X(65)90200-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(65)90200-7</ArticleId><ArticleId IdType="pubmed">5865501</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenger A.K., Jaffe A.S. Requiem for a Heavyweight: The Demise of Creatine Kinase-MB. Circulation. 2008;118:2200&#x2013;2206. doi: 10.1161/CIRCULATIONAHA.108.773218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.773218</ArticleId><ArticleId IdType="pubmed">19015414</ArticleId></ArticleIdList></Reference><Reference><Citation>Prellwitz W., Neumeier D. Creatine-Kinase and CK-MB Isoenzyme Activity in Serum of Patients after Surgical Operations, Polytrauma and Other Damage to Skeletal Muscle. Clin. Biochem. 1979;12:225. doi: 10.1016/S0009-9120(79)80108-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-9120(79)80108-3</ArticleId><ArticleId IdType="pubmed">535155</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvin M.D., Jaffe A.S., Ziegelstein R.C., Trost J.C. Eliminating Creatine Kinase&#x2013;Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. JAMA Intern. Med. 2017;177:1508. doi: 10.1001/jamainternmed.2017.3597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2017.3597</ArticleId><ArticleId IdType="pubmed">28806444</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Gomez S., Radermacher B., Tacik P., Mirandola S.R., Heneka M.T., Weydt P. Teaching an Old Dog New Tricks: Serum Troponin T as a Biomarker in Amyotrophic Lateral Sclerosis. Brain Commun. 2021;3:fcab274. doi: 10.1093/braincomms/fcab274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab274</ArticleId><ArticleId IdType="pmc">PMC8728713</ArticleId><ArticleId IdType="pubmed">34993474</ArticleId></ArticleIdList></Reference><Reference><Citation>Jockers-Wretou E., Grabert K., M&#xfc;ller E., Pfleiderer G. Serum Creatine Kinase Isoenzyme Pattern in Nervous System Atrophies and Neuromuscular Disorders. Clin. Chim. Acta. 1976;73:183&#x2013;186. doi: 10.1016/0009-8981(76)90322-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-8981(76)90322-3</ArticleId><ArticleId IdType="pubmed">1000828</ArticleId></ArticleIdList></Reference><Reference><Citation>Jockers-Wretou E., Vassilopoulos D. Serum Creatine Kinase B Subunit Levels in Neurogenic Atrophies. J. Neurol. 1985;232:236&#x2013;239. doi: 10.1007/BF00313786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313786</ArticleId><ArticleId IdType="pubmed">4045516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson S.B., Kasarskis E.J., Hu N., Pulst S.-M., Mendiondo M.S., Matthews D.E., Mitsumoto H., Tandan R., Simmons Z., Kryscio R.J., et al. Relationship of Creatine Kinase to Body Composition, Disease State, and Longevity in ALS. Amyotroph. Lateral Scler. Front. Degener. 2015;16:473&#x2013;477. doi: 10.3109/21678421.2015.1062516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062516</ArticleId><ArticleId IdType="pmc">PMC5595062</ArticleId><ArticleId IdType="pubmed">26312548</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Guan Y., Liu M., Li X., Shen D., Li D., Cui B., Fang J., Ding Q., et al. Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach R., Batyrbekova M., Gaur N., Voss A., Stubendorff B., Mayer T.E., Gaser C., Witte O.W., Prell T., Grosskreutz J. Applying the D50 Disease Progression Model to Gray and White Matter Pathology in Amyotrophic Lateral Sclerosis. Neuroimage Clin. 2020;25:102094. doi: 10.1016/j.nicl.2019.102094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.102094</ArticleId><ArticleId IdType="pmc">PMC6940701</ArticleId><ArticleId IdType="pubmed">31896467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xe4;ppe U., Chamoun S., Shen Q., Finn A., Evertsson B., Zetterberg H., Blennow K., Press R., Samuelsson K., M&#xe5;nberg A., et al. Cardiac Troponin T Is Elevated and Increases Longitudinally in ALS Patients. Amyotroph. Lateral Scler. Front. Degener. 2022;23:58&#x2013;65. doi: 10.1080/21678421.2021.1939384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1939384</ArticleId><ArticleId IdType="pubmed">34151677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittoo D., Jones A., Lecky B., Neithercut D. Elevation of Cardiac Troponin T, but Not Cardiac Troponin I, in Patients with Neuromuscular Diseases: Implications for the Diagnosis of Myocardial Infarction. J. Am. Coll. Cardiol. 2014;63:2411&#x2013;2420. doi: 10.1016/j.jacc.2014.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.03.027</ArticleId><ArticleId IdType="pubmed">24747102</ArticleId></ArticleIdList></Reference><Reference><Citation>Casmiro M., Graziani A. Serum Troponin T in Patients with Amyotrophic Lateral Sclerosis. Acta Neurol. Belg. 2019;119:285&#x2013;288. doi: 10.1007/s13760-017-0855-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-017-0855-y</ArticleId><ArticleId IdType="pubmed">29094271</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A., Schmid B., Buckert D., Rottbauer W., Kassubek J., Ludolph A.C., Bernhardt P. Cardiac Findings in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Imaging Study. Front. Neurol. 2017;8:479. doi: 10.3389/fneur.2017.00479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00479</ArticleId><ArticleId IdType="pmc">PMC5623666</ArticleId><ArticleId IdType="pubmed">29021775</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzvetanova E. Serum Creatine Kinase Isoenzymes in Progressive MuscularDystrophy. Enzyme. 1978;23:238&#x2013;245. doi: 10.1159/000458585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000458585</ArticleId><ArticleId IdType="pubmed">699895</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson B.M. The Biology of Long-Term Denervated Skeletal Muscle. Eur. J. Transl. Myol. 2014;24:3293. doi: 10.4081/bam.2014.1.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/bam.2014.1.5</ArticleId><ArticleId IdType="pmc">PMC4749001</ArticleId><ArticleId IdType="pubmed">26913125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg C., Klintberg L., Oldfors A. Raised Troponin T in Inclusion Body Myositis Is Common and Serum Levels Are Persistent over Time. Neuromuscul. Disord. 2006;16:495&#x2013;497. doi: 10.1016/j.nmd.2006.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2006.06.006</ArticleId><ArticleId IdType="pubmed">16920359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsung S.H., Huang T.Y., Lin J.I. Case Report CK-MB Isoenzyme in Patients with Polymyositis. Am. J. Med. Sci. 1982;283:174&#x2013;177. doi: 10.1097/00000441-198205000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-198205000-00011</ArticleId><ArticleId IdType="pubmed">7081291</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., Mills K., Mitsumoto H., Nodera H., Shefner J., et al. Electrodiagnostic Criteria for Diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>